- Home
- XLO vs INMB Comparison
XLO vs INMB Comparison
Compare XLO & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XLO | INMB |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 64.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | XLO | INMB |
|---|---|---|
| Price | $9.04 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $28.00 | $5.40 |
| AVG Volume (30 Days) | 9.2K | ★ 315.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,766,000.00 | $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $168.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | 257.14 |
| 52 Week Low | $0.46 | $1.09 |
| 52 Week High | $9.90 | $2.60 |
Technical Indicators
Market Signals| Indicator | XLO | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 43.69 |
| Support Level | $8.63 | $1.97 |
| Resistance Level | $9.15 | $2.17 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 21.83 | 15.15 |
Price Performance
Historical ComparisonAbout XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.